Instil Bio Inc (NASDAQ: TIL) is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of cancer. The company has generated no product revenue, funding operations through capital raises rather than commercial sales. As of the 10-K filed March 27, 2026, Instil Bio remained pre-commercial, with its Tarzana, California facility classified as held for sale and carrying an impairment charge of approximately $16.6 million recognized in the year ended December 31, 2025. The company previously operated manufacturing infrastructure in Manchester, United Kingdom, where equipment impairment charges of $4.3 million were recorded in the year ended December 31, 2024. Bronson Crouch serves as Chief Executive Officer, with Sandeep Laumas, M.D. also identified as a principal officer in the filing. The company has never paid dividends on its common stock and has no plans to do so, per the FY2025 10-K filing.

Revenue model

Instil Bio has not generated product revenue as of the 10-K filed March 27, 2026. Operations are funded through equity capital raises. The company carries no dividend obligation and disclosed an expected dividend yield of zero.

Products and services

The filing references cell therapy product candidates in clinical development for cancer treatment. No specific named product candidates are described in the available filing excerpts.

Customers and end markets

The end market is oncology, with patients in clinical trials as the primary subjects of the company's development programs. No commercial customers are disclosed in the available filing excerpts.

Value-chain role

Instil Bio occupies a clinical-stage drug developer role, conducting research, clinical trials, and manufacturing of cell therapy candidates. The company has been divesting manufacturing assets, including facilities in Tarzana, California and Manchester, United Kingdom, as of the FY2025 10-K filing.

Geographic exposure

Operations referenced in the FY2025 10-K include a Tarzana, California facility and previously active manufacturing equipment in Manchester, United Kingdom. No further geographic breakdown is supported by the available filing excerpts.

Source: SEC 10-K, filed 2026-03-27

Industry: Biological Products, (No Diagnostic Substances) Peers: Caribou Biosciences Inc CTI BIOPHARMA CORP IDEAYA Biosciences Inc INTERCEPT PHARMACEUTICALS, INC. iTeos Therapeutics, Inc. Mersana Therapeutics, Inc. Nkarta Inc Y-mAbs Therapeutics, Inc.